CytRx and Cephalon Oncology Therapies to be Evaluated as Treatment for Relapsed Acute Promyelocytic Leukemia.
Business Wire › September 14, 2009
Linked as:
Extract
CytRx and Cephalon Oncology Therapies to be Evaluated as Treatment for Relapsed Acute Promyelocytic Leukemia.
Clinical Trial Combining Tamibarotene with TRISENOX to Determine Appropriate Dose for Planned Phase 2 Trial as First-line and Follow-on Treatment for APL Patients
LOS ANGELES -- CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced the initiation of a dose escalation study with its oncology drug candidat...See the full content of this document
Sponsored links
